BioSpace News Archive

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units (“RSUs”) to Kenneth D. Knight, Invitae’s new Chief Operating Officer and Karthik Suri, Invitae’s new Chief Digital Officer.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share.

Samsung Biologics (KRX: 207940.KS) today held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.00 per share

Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with Inflammatory Bowel Disease (IBD), announced today the appointment of Keith Marshall, Ph.D., MBA as Chief Financial Officer.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2020.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming Canaccord Genuity 40th Annual Growth Conference.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with a single institutional investor for the purchase and sale for $10,000,000 of (i) 1,717,106 shares of common stock and (ii) 1,287,829 common stock

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 23,500 shares of Akebia’s common stock on July 31, 2020, as inducements material to each such employee’s entering into employment with Akebia.